3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.
1. A compound of the formula:
wherein Ar is a moiety selected from the group of:
X is selected from —CH 2 —, —O—, or —S—;
R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl;
or R 1 and R 2 together with the nitrogen atom to which they are bound form a 5-membered or 6-membered heterocyclic ring optionally containing one additional ring heteroatom selected from N or O;
R 3 is an alkyl group having from 3 to 8 carbon atoms or a polyhydroxylated alkyl group having from 3 to 8 carbon atoms;
R 4 is a polyhydroxylated alkyl group having from 3 to 8 carbon atoms; and
R 5 is selected from H or C 1 -C 3 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula:
wherein:
R 1 and R 2 are independently selected from H and C 1 -C 6 alkyl;
or R 1 and R 2 together with the nitrogen atom to which they are bound form a 5-membered or 6-membered heterocyclic ring optionally containing one additional ring heteroatom selected from N or O;
R 3 is an alkyl group having from 3 to 8 carbon atoms or a polyhydroxylated alkyl group having from 3 to 8 carbon atoms;
R 4 is a polyhydroxylated alkyl group having from 3 to 8 carbon atoms; and
R 5 is selected from H or C 1 -C 3 alkyl;
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 wherein the R 3 polyhydroxylated alkyl group has the formula —CH 2 —(CHR 5 ) n , wherein n is an integer selected from 2, 3, 4, 5, 6, or 7, and R 5 is independently in each instance H or OH, with the proviso that at least two of the R 5 groups are OH, or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 wherein the polyhydroxylated alkyl group has the formula —CH 2 —CHOH—(CHR 6 ) m , wherein m is an integer selected from 1, 2, 3, 4, 5, or 6, and R 6 is independently in each instance H or OH, with the proviso that at least one of the R 6 groups is OH, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 wherein the polyhydroxylated alkyl group has the formula —CH 2 —(CHOH) n —CH 2 OH, wherein n is an integer selected from 1, 2, 3, 4, 5, or 6, or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 wherein the polyhydroxylated alkyl group has the formula:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 wherein the polyhydroxylated alkyl group has the formula:
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
9. The composition of claim 8 , wherein said composition is suitable for inhalation.
10. The composition of claim 9 wherein said composition is a solution for aerosolization and administration by nebulizer, metered dose inhaler, or dry powder inhaler.
11. The pharmaceutical composition of claim 8 further comprising an osmolyte.
12. The pharmaceutical composition of claim 11 wherein the osmolyte is hypertonic saline.
13. The pharmaceutical composition of claim 11 wherein the osmolyte is mannitol.
14. The compound of claim 1 having a formula:
or a pharmaceutically acceptable salt thereof.